陈杰，1955年生，籍贯黑龙江巴彦县，病理学专家，北京协和医院教授，主任医师，博士生导师，北京协和医学院病理学系主任。1973年考入哈尔滨医科大学医疗系，1977年获得学士学位。1978年在中国协和医科大学病理学专业攻读硕士学位，1987年攻读博士学位。曾留学英国和美国，从事病理学研究。1991年升为副研究员。1994年升为主任医师、博士生导师。

主要从事胰腺肿瘤等人体肿瘤的分子病理学研究，包括肿瘤的发生机制、形态特点、分子改变、以及生物学特性等。

天美麻花星空

1. .Chen X, Ma H, Mo S, Zhang Y, Lu Z, Yu S, Chen J*. Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma. Front Immunol. 2022 Jul 22;13:942154. (IF=8.786)

2.Chen X, Mo S, Zong L, Yu S, Lu Z, Chen J*. A novel signature based on m6A RNA methylation regulators reveals distinct prognostic subgroups and associates with tumor immunity of patients with pancreatic neuroendocrine neoplasms. Neuroendocrinology. 2022 May 24. (IF=5.135)

3.Chen X, Mo S, Zhang Y, Ma H, Lu Z, Yu S, Chen J*. Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma. J Pathol Clin Res. 2022 May;8(3):268-278. (IF=5.638)

4. Liju Zong,Shengwei Mo, Shuangni Yu, Yuncan Zhou, Ming Zhang, Jie Chen*, Yang Xiang*. Expression of the immune checkpoint VISTA in breast cancer. Cancer Immunology, Immunotherapy (2020) 69:1437–1446. (IF=6.968)

5. Jie Yan, Shuangni Yu, Congwei Jia,Min Li, Jie Chen*. Molecular subtyping in pancreatic neuroendocrine neoplasms: new in sightsinto clinical, pathological unmet needs and challenges. Biochim Biophys Acta Rev Cancer. 2020 Aug;1874(1):188367. (IF=10.680)

6. H Yang, P Liu, J Zhang, X Peng, Z Lu, S Yu, Y Meng, W-M Tong and J Chen*.Long noncoding RNA MIR31HG exhibits oncogenic property in pancreatic ductal adenocarcinoma and is negativelyregulated by miR-193b. Oncogene (online, 2015.11). 2016, 35:3647–365. (IF=7.932, C100)

7.Yihui Ma, Shuangni Yu, Wugan Zhao, Zhaohui Lu, Jie Chen* .  miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2. Cancer Letters 2010; 298:150-158. (IF=4.864, C100)

8. Shuangni Yu, Zhaohui Lu, Changzheng Liu, Yunxiao Meng, Yihui Ma,Wugan Zhao, Jianping Liu, Jia Yu，and Jie Chen*.  miRNA-96 Suppresses KRAS and Functions as a Tumor Suppressor Gene in Pancreatic Cancer. Cancer Res  2010;70(14):6015-25. (IF=8.234, C100)

9. Wugan Zhao, Shuangni Yu, Zhaohui Lu, Yihui Ma, Yumei Gu, Jie Chen*. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis. 2010; 31(10):1726-1733. (IF=5.402, C100)

10.Chen Jie# and Baithun SI. Morphological study of 391 cases of exocrine pancreatic tumors with special reference to the classification of exocrine pancreatic carcinomas.  J Pathol 1985; 146:17-2. (IF=9.883, C100)